EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites37
Patients982

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	523
New Zealand	190
Finland	98
Switzerland	59
Saudi Arabia	47
Ireland	31
Belgium	18
Slovenia	12
Germany	4
Total	982